The dataset used in this study is available here: <http://doi.org/10.5281/zenodo.3886331>.

Background {#sec005}
==========

Patient organisations are increasingly involved with healthcare services and systems \[[@pone.0235021.ref001], [@pone.0235021.ref002]\] including in relation to pharmaceuticals \[[@pone.0235021.ref003], [@pone.0235021.ref004]\]. The increasing scope of activity results in patient organisations encountering many challenges in developing their capacity and expertise \[[@pone.0235021.ref001], [@pone.0235021.ref005]\]. Some of these challenges may be addressed by funding and other support provided by pharmaceutical companies \[[@pone.0235021.ref006], [@pone.0235021.ref007], [@pone.0235021.ref008], [@pone.0235021.ref009], [@pone.0235021.ref010], [@pone.0235021.ref011]\]. However, partnering with companies also raises concerns about conflicts of interest weakening patient organisations' independence from commercial agendas \[[@pone.0235021.ref004], [@pone.0235021.ref011],[@pone.0235021.ref012], [@pone.0235021.ref013], [@pone.0235021.ref014], [@pone.0235021.ref015], [@pone.0235021.ref016], [@pone.0235021.ref017], [@pone.0235021.ref018]\] that do not always coincide with the interest of patients and public health \[[@pone.0235021.ref019], [@pone.0235021.ref020]\]. For example, several industry-funded patient groups at the European Union level supported the industry's efforts to relax the ban on direct-to-consumer advertising, but this agenda was strongly opposed by patient groups that did not accept industry funding \[[@pone.0235021.ref021]\].

One response to these concerns has been to enhance the transparency of financial relationships between the two sides \[[@pone.0235021.ref022]\]. This is part of a global policy trend in which transparency, primarily understood as public disclosures, is applied to individuals' and organisations' ties to pharmaceutical companies \[[@pone.0235021.ref023], [@pone.0235021.ref024]\]. Perhaps the most comprehensive disclosure initiative pertaining to patient organisations has been introduced by the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing pharmaceutical companies operating in Europe, via its Patient Organisation Code of Practice \[[@pone.0235021.ref025]\]. Implemented through industry self-regulation since 2012, the Code requires pharmaceutical industry trade group members to disclose payments to patient organisations, which are typically published as annual reports on company websites \[[@pone.0235021.ref026]\].

As a result of this and similar transparency initiatives elsewhere in the world, there has been a spur in research on pharmaceutical company funding of patient organisations in the United Kingdom (UK) \[[@pone.0235021.ref004], [@pone.0235021.ref022], [@pone.0235021.ref026]\], Australia \[[@pone.0235021.ref027]\] and United States \[[@pone.0235021.ref028]\] using industry disclosure data. Industry disclosures have clear advantages over other data sources, such as surveys of patient organisations \[[@pone.0235021.ref014], [@pone.0235021.ref029]\] or their websites \[[@pone.0235021.ref030], [@pone.0235021.ref031]\], due to their greater coverage and standardisation \[[@pone.0235021.ref026]\]. The emerging picture from this research is that many patient organisations receive industry funding but that relatively few receive a large share of it \[[@pone.0235021.ref026], [@pone.0235021.ref027]\]. Most of the funding goes to research and public engagement, including advocacy, campaigning and disease awareness, and lobbying \[[@pone.0235021.ref026]\]. Furthermore, companies predominantly fund organisations in commercially high-profile areas, such as cancer and diabetes, indicating mercantile rather than philanthropically motivated support \[[@pone.0235021.ref026]\]. However, only a few countries have been surveyed making generalisations problematic, especially since the pattern of patient organisations' relations with industry may vary between countries \[[@pone.0235021.ref028]\].

Here, we contribute to building an internationally comparative body of knowledge by considering industry reports of payments to patient organisations in Sweden, using the same methodology as in the previous UK study \[[@pone.0235021.ref026]\]. Sweden has a history of pharmaceutical industry self-regulation \[[@pone.0235021.ref032]\] and a large patient organisation community: roughly 1 in 20 Swedes are affiliated to a patient organisation \[[@pone.0235021.ref033]\]. Another reason for selecting Sweden for this case study is that the Swedish pharmaceutical industry trade group (Läkemedelsindustriföreningen, LIF) has gone further than trade groups in other European countries that deem it sufficient to disclose payments on the sponsoring company's webpage, and which in the UK was shown to make it near-impossible to establish the scope of industry involvement for any patient organisation \[[@pone.0235021.ref022], [@pone.0235021.ref026]\]. In contrast--and consistent with recommendations from the UK \[[@pone.0235021.ref022]\]--since 2005 LIF has a centralised and searchable (albeit not downloadable) database where companies upload reports for every payment. The aims of this study were therefore to assess:

-   the pattern of industry engagement with patient organisations by looking at available payment reports

-   the association between drug commercialisation and industry funding of patient organisations

-   the advantages of a centralised database for identifying and understanding the nature of industry funding of patient organisations

Methods {#sec006}
=======

Data and coding {#sec007}
---------------

We extracted 1,412 payment reports from the Swedish pharmaceutical industry's trade group's "collaboration database" \[[@pone.0235021.ref034]\], covering a 5-year period, from January 2014 to December 2018. We selected a 5-year period to have a fairly large but still manageable sample, but also because industry rules allow reports to be deleted after three years which limited data availability. Data was collected in two phases: data from January 2014 to December 2016 were collected in November and December 2016, and data from January 2017 to December 2018 were collected in April and May 2019. Two authors (SM and AV) manually extracted the data into an Excel database, including the report title, project start and end dates, sponsoring company, recipient organisation, and project and payment descriptions, which are all contained in separate fields. SM extracted the data from January 2014 to December 2016 and AV the data from January 2017 to December 2018 in dialogue with SM. AV checked the data extracted by SM from June 2016 to December 2016 but found no discrepancies. Each entry was coded separately for payment category (e.g. sponsorship, grant, fees for service and consultancy) and goal (e.g. policy engagement, education and training) \[[@pone.0235021.ref026]\]. Given our focus on the national level, we aggregated local and regional patient organisations into their parent national association. Each patient organisation was coded according to their condition and disease area using ICD-10 (International Classification of Diseases, 10th revision). Most payments were reported in Sweden's currency, SEK. We expressed all payments in 2018 EUR using average annual exchange rates available from Sweden's Central Bank. To adjust for inflation, we used a yearly consumer price index obtained from Statistics Sweden (2014 = 4.76%, 2015 = 4.81%, 2016 = 3.79%, 2017 = 1.95%, 2018 = 0).

Descriptive data analysis {#sec008}
-------------------------

To examine the pattern of the disclosed payments, we performed descriptive analyses calculating the number, value and distribution (median, interquartile range (IQR)) of payments. The descriptive analysis was specified beforehand to the following units of analysis validated in a previous UK study \[[@pone.0235021.ref026]\]: all companies and patient organisations, individual companies and patient organisations, condition and disease areas, and payment categories and goals ([S1 Table](#pone.0235021.s001){ref-type="supplementary-material"}). In short, the payment category codes were initially devised based on the codes used by EFPIA to categorise pharmaceutical company payments to healthcare organisations (e.g. hospitals, universities, medical associations), specifically, "grants", "contributions to costs of events", "travel, accommodation and registration fees", "fees for service and consultancy", and "sponsorship"'. These codes were then supplemented with an inductive approach for any emerging payment categories that were unique to the patient organisation payment descriptions, such as "support and help" \[[@pone.0235021.ref022], [@pone.0235021.ref026]\]. Separately, payment goal was coded based on close iterative reading of payment descriptions and aggregating similar descriptions under the same codes \[[@pone.0235021.ref022], [@pone.0235021.ref026]\]. When coding payment goals we looked for the main purpose of activities funded by drug companies. Furthermore, for each patient organisation, condition and disease area, we identified the supporting companies as well as the main donor's share of the overall funding.

During the coding, we realised that a substantial amount of the funding--especially of policy engagement and advocacy--concentrated to the so-called Politician's Week held every summer, known nationally also as the Almedalen Week, which we therefore included as another unit of analysis. The Politician's Week can be described as a micro-cosmos of Swedish politics where politicians, ministerial advisors, governmental and special interest organisations, companies, think thanks, lobbyist, policy- and PR consultants and journalists, gather for debate, advocacy and lobbying, marketing, and social and political networking. Thus, Politician's Week funding may provide special insight into joint lobbying efforts.

Association between drug commercialisation and industry funding {#sec009}
---------------------------------------------------------------

We began by assessing the concordance (Cohen\'s κ) between companies marketing drugs in specific ICD-10 disease areas and their funding of corresponding patient organisations. To make the analysis practical, we considered the top ten donors overall in the ten most funded disease areas. The online Swedish Medicines Compendium--FASS--has webpages for every pharmaceutical company which lists all products marketed in Sweden with weblinks to the Summary of Products Characteristics that contain information on approved indications. We used information on approved indications to determine whether or not companies marketed at least one drug in each of the ten selected diseases. For a drug to be considered marketed in a disease it had be indicated for the disease, e.g. drugs approved in HIV/AIDS patients for combating non-HIV infections, such as fungal infections, were not HIV drugs. Similarly, analgesics indicated for cancer patients were not cancer drugs.

In a separate analysis we calculated the correlation between the commercialisation of new drugs in ICD-10 condition areas and payments to patient organisations in those condition areas by all LIF companies over the study period. We performed the analysis at the level of broader conditions (e.g. neoplasms), rather than narrower diseases (e.g. breast or prostate cancers), because the former is less sensitive to the fact that our drug sample for this analysis only included drugs approved 2014--2018 and that drugs' indications may broaden over time. Furthermore, an important share of the funding, especially to cancer patient organisations, could not be differentiated at the level of specific diseases. In a first step, we compiled data on all new prescription drugs (i.e. New Active Substances (NAS) but excluding vaccines) from LIF companies that were approved by the European Medicines Agency (EMA) between 2014--2018, including information on date of approval, drug company and approved indication, based on information on the EMA and FASS websites. Next, we coded the drugs according to ICD-10 categories. Finally, using Spearman's rank-order correlation, we assessed the correlation between the number of new drugs approved in 2014--2018 for various ICD-10 conditions as well as the number of LIF companies marketing these drugs per ICD-10 condition area and, separately, the number and value of payments in ICD-10 condition areas. Spearman's rank-order correlation, rather than Pearson correlation, was chosen because of the large number of cancer drugs and payments to cancer patient organisations. A p-value below 0.05 was considered significant. Prism 8.2.1 for Macintosh (GraphPad Software Inc.) was used all statistical analyses.

Results {#sec010}
=======

Overview of industry payments {#sec011}
-----------------------------

Over the 5-year period, 2014--2018, 46 pharmaceutical companies reported 1,412 relationships with the local, regional or national branches of 77 patient organisations. However, 75 reports (5.3%) lacked information on the value of the payment, in violation of industry rules, and were subsequently excluded. This left us with 1,337 reports totalling €6,449,224, including 56 (4.2%) reporting zero-value payments (i.e. relationships without financial support). As shown in [Table 1](#pone.0235021.t001){ref-type="table"}, there was an increase of annual payments between 2014--2016, reaching €1,583,581 (n = 298) in 2016, followed by a drop in 2017 and in 2018 --to €1,091,558 (n = 257). The funding landscape was dominated by small payments with roughly one quarter being smaller than €1,000 (26.0%; n = 348), and three quarters (77.9%; n = 1041) below €5,000 (median €2,411; IQR €1,024--4,569). However, the ten largest payments constituted roughly 15% of the total value (€942,623).

10.1371/journal.pone.0235021.t001

###### Reported drug company payments to patient organisations in Sweden (2014--18).
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                                     2014                     2015                     2016                   2017                     2018                   All years
  ---------------------------------- ------------------------ ------------------------ ---------------------- ------------------------ ---------------------- ------------------------
  **Value of payments (€)**          1 261 999                1 350 447                1 583 581              1 161 639                1 091 558              6 449 224
  **Median (IQR) (€)**               2 879 (1 152 to 5 758)   2 912 (1 055 to 6 676)   2 192 (937 to 3 933)   2 117 (1 058 to 4 234)   2 214 (887 to 3 900)   2 411 (1 024 to 4 569)
  **No. of payments**                244                      271                      298                    267                      257                    1 337
  **No. of drug companies**          32                       33                       37                     33                       29                     46
  **No. of patient organisations**   39                       45                       54                     50                       40                     77

Donors and recipients {#sec012}
---------------------

There was a high concentration of payments among companies. The top ten donors provided 67.9% (€4,379,604) of the funding ([Table 2](#pone.0235021.t002){ref-type="table"}; [S2 Table](#pone.0235021.s002){ref-type="supplementary-material"} for full table). Pfizer was the major donor with 14.8% (€954,234) of the reported funding whereas AbbVie had the greatest number of payments (10.9%; n = 146). Pfizer also made the largest single payment, worth €353,179, to the Swedish Breast Cancer Association in 2016 to support the creation of a website for information dissemination and advocacy ([S3 Table](#pone.0235021.s003){ref-type="supplementary-material"}). Pfizer also made the second largest payment to the same patient organisation in 2018 worth €97,497 supporting the same project. Besides Pfizer, AbbVie was the only other company that had more than one payment in the top ten.

10.1371/journal.pone.0235021.t002

###### Top ten drug companies reporting payments to patient organisations in Sweden (2014--18).
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  Company           Value of payments. € (%)[^1^](#t002fn001){ref-type="table-fn"}   n (%)[^2^](#t002fn002){ref-type="table-fn"}
  ----------------- ---------------------------------------------------------------- ---------------------------------------------
  Pfizer            954 234 (14.8)                                                   92 (6.9)
  AbbVie            731 902 (11.3)                                                   146 (10.9)
  Sanofi            447 812 (6.9)                                                    87 (6.5)
  Roche             404 049 (6.3)                                                    131 (9.8)
  Novartis          403 508 (6.3)                                                    95 (7.1)
  GlaxoSmithKline   383 346 (5.9)                                                    43 (3.2)
  Janssen           335 870 (5.2)                                                    85 (6.4)
  Bayer             260 900 (4.0)                                                    57 (4.3)
  Celgene           243 880 (3.8)                                                    64 (4.8)
  Amgen             214 103 (3.3)                                                    64 (4.8)
  **Total**         **4 379 604 (67.9)**                                             **864 (64.6)**

^1^ Percent of total value of payments (€6,449,224)

^2^ Percent of total number of payments (1,337)

As shown in [Table 3](#pone.0235021.t003){ref-type="table"}, there was also a high degree of concentration of payments among patient organisations. Of the 77 patient organisations that received funding, the top ten recipients amassed 62.4% (€4,026,410), and the top recipient, the Swedish Breast Cancer Association, alone received 10.3% (€663,774), from just five companies. The Network Against Cancer--an umbrella coalition of cancer patient and advocacy organisations and networks--had the greatest number of company funders (n = 16) but was only the fourth most funded organisation.

10.1371/journal.pone.0235021.t003

###### Ten most funded patient organisations by reporting drug companies in Sweden (2014--18).
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  Patient organisation                                               Value of payments, € (%)[^1^](#t003fn001){ref-type="table-fn"}   n (%)[^2^](#t003fn002){ref-type="table-fn"}   Number of supporting companies   Main donor, € (%)[^3^](#t003fn003){ref-type="table-fn"}
  ------------------------------------------------------------------ ---------------------------------------------------------------- --------------------------------------------- -------------------------------- --------------------------------------------------------------
  Breast Cancer Association                                          663 774 (10.3)                                                   62 (4.6)                                      5                                Pfizer, 492 074 (74.1)
  Blood Cancer Association                                           568 107 (8.8)                                                    131 (9.8)                                     10                               Novartis, 157 338 (27.7)
  Association for gastro-intestinal diseases                         469 576 (7.3)                                                    49 (3.7)                                      11                               AbbVie, 141 150 (30.1)[^4^](#t003fn004){ref-type="table-fn"}
  The Network Against Cancer[^5^](#t003fn005){ref-type="table-fn"}   397 451 (5.7)                                                    117 (8.7)                                     16                               Celgene, 48 310 (12.2)
  Heart and Lung Association                                         381 914 (5.9)                                                    67 (5.0)                                      10                               Pfizer, 84 253 (22.1)
  Rheumatism Association                                             353 739 (5.5)                                                    55 (4.1)                                      13                               AbbVie, 124 141 (35.1)
  Prostate Cancer Federation                                         338 684 (5.2)                                                    134 (10.0)                                    8                                Astellas, 148 674 (43.9)
  Hemophilia Society                                                 321 315 (5.0)                                                    65 (4.9)                                      11                               Bayer, 90 404 (28.1)
  Neuro                                                              280 757 (4.3)                                                    50 (3.7)                                      9                                Biogen, 126 091 (44.9)
  1.6 Million Club[^6^](#t003fn006){ref-type="table-fn"}             251 093 (3.9)                                                    32 (2.3)                                      8                                Bayer, 63 394 (25.2)
  **Total**                                                          **4 026 410 (62.4)**                                             **762 (57.0)**                                                                 

^1^ Percent of total value of payments (€6,449,224)

^2^ Percent of total number of payments (1,337)

^3^ Percent of total value of payments received by the patient organisation

^4^ In addition, AbbVie made two payments worth €62,677 together with Bristol-Myers-Squibb. Because no information was provided on how co-funding was shared between the two companies, the two payments are not included here.

^5^ The Network Against Cancer is a coalition of cancer patient organisations, advocacy organisations and networks, such as Swedish Childhood Cancer Fund, Blood Cancer Association, Cancer Society of PALEMA (pancreas, liver, stomach and oesophagus), Swedish Association of Lymphoedema, ILCO (colorectal and ostomy cancer), Lung Cancer Association, and Gynsam--National Gynaecological Cancer Patients Coalition.

^6^ 1.6 Million Club: a non-profit women's health organisation; at the time of organisational launch, there were 1.6 million women above 45 years of age in Sweden.

Category and goal of funding {#sec013}
----------------------------

The top funding priority was supporting patient organisations' engagement with outside audiences ([Table 4](#pone.0235021.t004){ref-type="table"}). Thus, the most common payment *category* was "contribution to costs of events" organised by the recipient patient organisation or third parties, for example an external meeting or lecture, attracting 35.7% (€2,300,750). Other main payment categories were "support and help" (20.5%; €1,325,363), "partnership arrangements" (15.8%; €1,021,968) and "sponsorships" (12.9%; €831,430).

10.1371/journal.pone.0235021.t004

###### Top 10 payment categories and goals in Sweden (2014--18).
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  --------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Category**                                                                            **Payment, € (%)**[^**1**^](#t004fn001){ref-type="table-fn"}   **Median, € (IQR)**       **n (%)**[^**2**^](#t004fn002){ref-type="table-fn"}   **Example (abbreviated)**
  Contributions to costs of events organised by recipients or third parties               2 300 750 (35.7)                                               2 170 (1 088 to 3 451)    767 (57.4)                                            Contribution to cover rent, lecturers, study material, food, marketing of meetings, and media processing for event
  Support and help                                                                        1 325 363 (20.5)                                               4 683 (1 984 to 10 266)   104 (7.8)                                             Support for creation of website for disseminating information on breast cancer
  Partnership arrangements                                                                1 021 968 (15.8)                                               5 484 (2 564 to 11 020)   104 (7.8)                                             A joint seminar to discuss a Hepatitis C national action plan with government representatives and politicians
  Sponsorships                                                                            831 430 (12.9)                                                 5 466 (2 149 to 10 587)   108 (8.1)                                             Sponsorship of annual campaign on prostate cancer and men's health
  Grants                                                                                  248 411 (3.9)                                                  5 601 (3 167 to 7 671)    31 (2.3)                                              Grant to be used for leaflet on metastatic breast cancer, multiple events for young women with breast cancer, four advertisements in patient organisation magazine, and printed materials to support an app.
  Form of funding unclear                                                                 181 610 (2.8)                                                  1 024 (0 to 2 964)        32 (2.4)                                              Un-specified project costs
  More than one distinct payment form                                                     154 362 (2.4)                                                  6 721 (2 192 to 14 136)   13 (1.0)                                              Four different payments to four different projects organised by the patient organisation
  Travel, accommodation and registration fees                                             67 566 (1.0)                                                   1 002 (560 to 2 062)      46 (3.4)                                              Cover cost of travel, transfer, accommodation and meals for one patient organisation member attending conference
  Sponsorship of participation at events organised by drug companies                      66 134 (1.0)                                                   548 (296 to 1 400)        39 (2.9)                                              Cover cost of one speaker from patient organisation to attend company conference
  Fees for service and consultancy (including travel and accommodation)                   54 548 (0.8)                                                   553 (339 to 1 108)        34 (2.5)                                              Payment to patient organisation for 29 hours of work checking text for a company web site
  **Goal**                                                                                **Payment, € (%)**[^**1**^](#t004fn001){ref-type="table-fn"}   **Median, € (IQR)**       **n (%)**[^**2**^](#t004fn002){ref-type="table-fn"}   **Example (abbreviated)**
  Communication in general, media, meetings, online, publications, skills development     2 041 674 (31.7)                                               1 885 (983 to 3 361)      609 (30.6)                                            Financial support for online initiative to acknowledge World Pancreatic Cancer Day
  Advocacy, campaigning, and disease awareness                                            1 707 507 (26.5)                                               3 551 (2 136 to 8 177)    242 (18.1)                                            Support for communication activities (media invitation and event) seeking to raise awareness of burden of kidney disease
  Education and training                                                                  736 816 (11.4)                                                 3 175 (1 264 to 6 017)    146 (10.9)                                            Sponsorship to organise two-day educational meeting
  More than one distinct purpose mentioned                                                733 274 (11.4)                                                 3 620 (1 758 to 10 412)   42 (3.1)                                              Contribution to maintenance, update and development of website, and to the work of certifying incontinence clinics in Sweden
  Patient support                                                                         356 801 (5.5)                                                  2 996 (1 509 to 5 609)    51 (3.8)                                              Funding for evaluating and developing digital patient tool
  Policy engagement                                                                       204 416 (3.2)                                                  3 289 (3 144 to 5 186)    43 (3.2)                                              Support for creation of a platform for stakeholders to meet, discuss and debate cancer issues, including with purpose to influence decision-makers to provide more resources to cancer care
  Accessing or paying for organisation\'s expertise                                       146 256 (2.3)                                                  548 (224 to 1 112)        85 (6.4)                                              Financial compensation and travel expenses for patient organisation member to give lecture at internal company conference
  Support for fundraising                                                                 127 009 (2.0)                                                  6 048 (5 041 to 12 382)   8 (0.6)                                               Financial support to organise charity-gathering event before annual World Diabetes Day
  Inputting to organisation\'s work via membership, partnership, sponsorship or support   108 399 (1.7)                                                  2 134 (941 to 3 456)      35 (2.6)                                              Support on site when preparing and serving Christmas lunch during organisation's Christmas celebration
  Funding for awards                                                                      78 800 (1.2)                                                   5 292 (1 400 to 5 680)    15 (1.1)                                              Company donation to a fund that annually award research grants on bleeding disorders
  Research                                                                                59 544 (0.9)                                                   5 041 (1 955 to 9 526)    11 (0.8)                                              For patient organisation to help with a company's European study, with members encouraged to fill in survey linked from the organisation's Facebook page.
  --------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Percent of total value of payments (€6,449,224)

^2^ Percent of total number of payments (1,337)

Furthermore--looking at the *goal* of the funding--public involvement, including "communication", "advocacy, campaigning and disease awareness" and "policy engagement" together attracted the lion's share of the funding (61.3%: €3,953,597). In contrast, "support for patients" attracted just 5.5% (€356,801) and "research-related activities" 0.9% (€59,544).

There were some payments for which the category or the goal of funding (or both) could not be determined due to lack of information, totalling €181,610 (2.8%) and €59,228 (0.9%), respectively.

Conditions and diseases {#sec014}
-----------------------

[Table 5](#pone.0235021.t005){ref-type="table"} reports on broad condition areas and narrower disease areas by amount of funding received. Of the 17 ICD-10 condition areas, the top five amassed 69.6% (€4,485,252), with neoplasms alone attracting 37.5% (€2,419,186). This was followed by infectious and parasitic (9.1%; €590,026), endocrine, nutritional and metabolic (9.1%; €587,605), musculoskeletal (6.9%; €446,718) and digestive system (6.8%; €441,717) diseases.

10.1371/journal.pone.0235021.t005

###### Reported drug industry funding of patient organisations in Sweden across condition and disease areas (2014--18).
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  Condition and Disease area                                                                          ICD-10 code                                            Payment, € (%)                                                       n (%)                                                          Supporting companies   Main donor,€ (%)
  --------------------------------------------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------------------------- ---------------------- ----------------------------------------------------------------------------
  ***Neoplasms***                                                                                     ***C00-D49***                                          ***2 419 186 (37*.*5)***[^**1**^](#t005fn001){ref-type="table-fn"}   ***606 (45*.*3)***[^**2**^](#t005fn002){ref-type="table-fn"}   ***22***               ***Pfizer*, *619 662 (25*.*6)***[^**3**^](#t005fn003){ref-type="table-fn"}
  Breast                                                                                              C50                                                    663 774 (27.4)[^**3**^](#t005fn003){ref-type="table-fn"}             62 (10.2)[^**4**^](#t005fn004){ref-type="table-fn"}            5                      Pfizer, 492 074 (74.1)[^**5**^](#t005fn005){ref-type="table-fn"}
  Lymphoid, hematopoietic and related tissue                                                          C81-C96                                                463 378 (19.2)                                                       121 (20.0)                                                     10                     Celgene, 121 363 (26.2)
  General                                                                                             C00-D49                                                416 250 (17.2)                                                       122 (20.1)                                                     16                     Roche, 52 592 (12.6)
  Male genital organs (all prostate)                                                                  C61                                                    338 684 (14.0)                                                       134 (22.1)                                                     8                      Astellas, 148 674 (43.9)
  Respiratory and intrathoracic organs (all lung)                                                     C30-C39                                                153 225 (6.3)                                                        50 (8.3)                                                       11                     Roche, 43 012 (28.1)
  Digestive organs                                                                                    C15-C26                                                129 852 (5.4)                                                        46 (7.6)                                                       7                      Roche, 60 015 (46.2)
  Neuroendocrine                                                                                      C7A                                                    86 227 (3.6)                                                         35 (5.8)                                                       3                      Novartis, 31 075 (36.0)
  Of uncertain behavior, polycythemia vera and myelodysplastic syndromes                              D37-D48                                                81 847 (3.4)                                                         8 (1.3)                                                        2                      Novartis, 70 718 (86.4)
  Female genital organs                                                                               C51-C58                                                46 487 (1.9)                                                         15 (2.5)                                                       4                      Roche, 19 604 (42.2)
  Urinary tract                                                                                       C64-C65                                                19 122 (0.8)                                                         7 (1.2)                                                        4                      Pfizer, 8 705 (45.5)
  Eye, brain and other parts of central nervous system                                                C71                                                    19 165 (0.8)                                                         4 (0.7)                                                        1                      Roche, 19 165 (100)
  Skin                                                                                                C49                                                    1 523 (0.1)                                                          2 (0.3)                                                        2                      Eli Lilly, 975 (64.0)
  ***Certain infectious and parasitic***                                                              ***A00-B99***                                          ***590 026 (9*.*1)***                                                ***105 (7*.*9)***                                              ***9***                ***GSK*, *360 702 (62*.*1)***
  HIV                                                                                                 B20-B24                                                469 074 (79.5)                                                       60 (57.1)                                                      5                      GSK, 360 702 (76.9)
  Hepatitis C                                                                                         B18.2                                                  109 481 (18.6)                                                       39 (37.1)                                                      4                      AbbVie, 96 526 (95.4)
  Both HIV and Hepatitis C                                                                            B18.2, B20                                             8 391 (1.4)                                                          4 (3.8)                                                        1                      AbbVie, 8 391 (100)
  Other                                                                                               A84.1                                                  3 080 (0.5)                                                          2 (1.9)                                                        1                      Pfizer, 3 080 (100)
  ***Endocrine*, *nutritional and metabolic***                                                        ***E00-E90***                                          ***587 605 (9*.*1)***                                                ***121 (9*.*0)***                                              ***14***               ***Sanofi*, *240 600 (40*.*9)***
  Diabetes (Type 1 or 2)                                                                              E10, E11                                               340 972 (58.0)                                                       79 (65.3)                                                      9                      Boehringer Ingelheim, 86 889 (25.5)
  Familial hypercholesterolemia                                                                       E78.0                                                  162 742 (27.7)                                                       6 (5.0)                                                        2                      Sanofi, 157 701 (96.9)
  Other                                                                                               E20.9; E27.1; E34.3; E66; E75.22; E76; E85.1; E88.01   65 318 (11.1)                                                        24 (19.8)                                                      6                      Shire, 24 255 (37.1)
  Fabry Disease                                                                                       E75.21                                                 18 086 (3.1)                                                         11 (9.1)                                                       2                      Shire, 9 125 (50.4)
  ***Musculoskeletal system and connective tissue***                                                  ***M00-99***                                           ***446 718 (6*.*9)***                                                ***78 (5*.*8)***                                               ***13***               ***124 141 (27*.*8) AbbVie***
  Rheumatisms (various forms)                                                                         M05-06; M08                                            319 150 (71.4)                                                       45 (57.7)                                                      11                     AbbVie, 124 141 (38.9)
  Osteoporosis                                                                                        M80-M81                                                115 151 (25.8)                                                       27 (34.6)                                                      3                      Amgen, 99 854 (86.8)
  Other                                                                                               M32; M45                                               12 417 (2.8)                                                         6 (7.7)                                                        2                      Novartis, 6 575 (52.9)
  ***Digestive system***                                                                              ***K00-K95***                                          ***441 717 (6*.*8)***                                                ***53 (4*.*0)***                                               ***11***               ***AbbVie*, *141 150 (32*.*0)***
  Noninfective enteritis and colitis including Crohn's                                                K50-52                                                 302 435 (68.5)                                                       25 (47.2)                                                      5                      AbbVie, 138 017 (61.2)
  Other                                                                                               K00-95; K59; K90                                       139 282 (31.5)                                                       28 (52.8)                                                      9                      Takeda, 82 972 (59.6)
  ***Nervous system***                                                                                ***G00-99***                                           ***437 788 (6*.*8)***                                                ***83 (6*.*2)***                                               ***17***               ***Biogen*, *126 091 (28*.*9)***
  Other                                                                                               G10-G99, G12; G24; G40; G44                            186 102 (42.5)                                                       34 (41.0)                                                      12                     Novartis, 40 241 (21.6)
  Multiple Sclerosis                                                                                  G35                                                    143 060 (32.7)                                                       23 (27.7)                                                      6                      Biogen, 106 122 (74.2)
  Parkinson's, Alzheimer's                                                                            G20; G30                                               108 626 (24.8)                                                       26 (31.3)                                                      8                      AbbVie, 77 334 (71.2)
  ***Blood and blood-forming organs and certain disorders involving the immune mechanism***           ***D50-89***                                           ***397 759 (6*.*2)***                                                ***81 (6*.*1)***                                               ***11***               ***CSL Behring*, *115 213 (29*.*0)***
  Haemophilia                                                                                         D65-D69                                                321 133 (80.7)                                                       64 (79.0)                                                      11                     Bayer, 90 404 (28.2)
  Immunodeficiency                                                                                    D84                                                    50 800 (12.8)                                                        12 (14.8)                                                      4                      CSL Behring, 42 966 (84.6)
  Other                                                                                               D56; 61; 84.1                                          25 826 (6.5)                                                         5 (6.2)                                                        4                      Novartis, 22 865 (88.5)
  ***Circulatory system***                                                                            ***I00-99***                                           ***297 491 (4*.*6)***                                                ***50 (3*.*7)***                                               ***10***               ***Pfizer*, *94 870 (31*.*9)***
  General                                                                                             I10-I99; I48; I26-I52                                  187 310 (63.0)                                                       23 (46.0)                                                      8                      Pfizer, 81 825 (43.7)
  Atrial fibrillation                                                                                 I48                                                    55 387 (18.6)                                                        10 (20.0)                                                      5                      Boehringer Ingelheim, 36 584 (66.1)
  Cerebral infarction/Stroke                                                                          I63                                                    30 789 (10.3)                                                        4 (8.0)                                                        1                      Bayer, 30 789 (100)
  Others                                                                                              I27; I81-I82; I89                                      26 884 (9.0)                                                         14 (28.0)                                                      4                      Actelion, 9 924 (36.9)
  ***Skin and subcutaneous tissue***                                                                  ***L00-L99***                                          ***245 964 (3*.*8)***                                                ***36 (2*.*7)***                                               ***9***                ***AbbVie*, *129 599 (52*.*7)***
  Psoriasis                                                                                           L40; L40.50                                            219 709 (89.3)                                                       32 (88.9)                                                      8                      AbbVie, 103 626 (47.2)
  Other                                                                                               L20; L73.2                                             26 255 (10.7)                                                        4 (11.1)                                                       2                      AbbVie, 25 973 (98.9)
  ***Various***                                                                                       ***N/A***                                              **200 863 (3.1)**                                                    **36 (2.7)**                                                   ***14***               ***Pfizer*, *55 326 (27*.*5)***
  Women's health                                                                                      N/A                                                    108 758 (54.1)                                                       16 (44.4)                                                      5                      Pfizer, 55 326 (50.9)
  Other                                                                                               N/A                                                    92 105 (45.9)                                                        20 (55.6)                                                      11                     Sanofi, 33 842 (36.7)
  ***Respiratory system***                                                                            ***J00-J99***                                          ***180 235 (2*.*8)***                                                ***37 (2*.*8)***                                               ***8***                ***Pfizer*, *52 060 (28*.*9)***
  COPD                                                                                                J40-J44                                                148 958 (82.6)                                                       27 (73.0)                                                      6                      Pfizer, 52 060 (34.9)
  Asthma                                                                                              J45                                                    17 985 (10.0)                                                        4 (10.8)                                                       2                      GlaxoSmithKline, 16 802 (93.4)
  Lung fibrosis                                                                                       J84.1                                                  13 292 (7.4)                                                         6 (16.2)                                                       2                      Roche, 7 947 (59.8)
  ***Certain conditions originating in the perinatal period***                                        ***P00-P96***                                          ***67 177 (1*.*0)***                                                 ***16 (1*.*2)***                                               ***3***                ***AbbVie*, *62 844 (93*.*5)***
  Preterm newborn                                                                                     P07                                                    67 177 (100)                                                         16 (100)                                                       3                      AbbVie, 62 844 (93.5)
  ***Congenital malformations*, *deformations and chromosomal abnormalities***                        ***Q00-Q99***                                          ***55 330 (0*.*9)***                                                 ***15 (1*.*1)***                                               ***4***                ***Novartis*, *39 454 (71*.*3)***
  Tuberous sclerosis                                                                                  Q85.1                                                  39 454 (71.3)                                                        9 (60.0)                                                       1                      Novartis, 39 454 (100)
  Other                                                                                               Q61, Q87.1, Q96                                        15 876 (28.7)                                                        6 (40.0)                                                       3                      Otsuka, 11 404 (71.8)
  ***Mental*, *Behavioural and Neurodevelopmental***                                                  ***F01-F99***                                          ***42 911 (0*.*7)***                                                 ***13 (1*.*0)***                                               ***6***                ***Janssen*, *17 192 (40*.*1)***
  Schizophrenia                                                                                       F20                                                    29 250 (68.2)                                                        7 (53.8)                                                       4                      Janssen, 15 117 (51.7)
  ADHD                                                                                                F90                                                    10 373 (24.2)                                                        5 (38.5)                                                       4                      Novartis, 5 716 (55.1)
  Other                                                                                               F11.10                                                 3 288 (7.7)                                                          1 (7.7)                                                        1                      Shire, 3 288 (0.1)
  ***Symptoms*, *signs and abnormal clinical and laboratory findings*, *not elsewhere classified***   ***R00-99***                                           ***20 176 (0*.*3)***                                                 ***4 (0*.*3)***                                                ***2***                ***Astellas*, *14 884 (73*.*8)***
  Various                                                                                             R32; R61                                               20 176 (100)                                                         4 (100)                                                        2                      Astellas, 14 884 (73.8)
  ***Eye and adnexa***                                                                                ***H00-H59***                                          10 959 (0.2)                                                         1 (0.1                                                         ***1***                ***Santen*, *10 959 (100)***
  Glaucoma                                                                                            H40                                                    10 959 (100)                                                         1 (100)                                                        1                      Santen, 10 959 (100)
  ***Genitourinary system***                                                                          ***N00-99***                                           ***7 319 (0*.*1)***                                                  ***4 (0*.*3)***                                                ***4***                ***Otsuka*, *2 879 (39*.*3)***
  Various kidney                                                                                      N25.81                                                 7 319 (100)                                                          4 (100)                                                        4                      Otsuka, 2 879 (39.3)

^1^ Percent of total value of payments (€6,449,224)

^2^ Percent of total number of payments (1,337)

^3^ Percent of total value of payments to condition area

^4^ Percent of total number of payments to condition area

^5^ Percent of total value of payments to disease area

However, within the broader condition areas, we observed a clear hierarchy among diseases. Thus, within neoplasms, cancers of breast, blood (lymphoid, hematopoietic and related tissues) and prostate amassed the bulk of funding (60.6%) whereas, for example, cancer of the female genital organs (1.9%) and skin (0.1%) received comparably little funding. This pattern was even more evident for some other condition areas. For example, virtually all funding for infectious and parasitic diseases went to HIV and hepatitis C. Overall, the top ten diseases in terms of funding accumulated 58.6% (€3,777,683). By far, most funding went to breast cancer with 10.3% (€663,774), followed by HIV (7.3%; €469,074) and blood cancers (7.2%; €463,378).

As shown in [Table 5](#pone.0235021.t005){ref-type="table"}, companies tended to invest selectively and heavily in certain disease areas, which had a major effect on the overall pattern of funding. Pfizer, for example, provided most of the funding of breast cancer advocacy (74.1%; €492,074). Similarly, Astellas provided 43.9% (€148,674) of the funding of prostate cancer advocacy, whereas GlaxoSmithKline dominated HIV (76.9%; €360,702) and AbbVie Psoriasis (47.2%; €103,626) and hepatitis C (95.4%; €96,526) funding. At the same time, certain disease areas had many funders, such as cancers in general (n = 16) and blood cancers (n = 10) and diabetes (n = 9), resulting in overall substantial sums.

The politician\'s week: Joint industry-patient organisation lobbying {#sec015}
--------------------------------------------------------------------

A particular aspect of the industry funding landscape in Sweden was the substantial and recurrent funding of patient organisations during the yearly Politician's Week, or Almedalen Week. Payment reports shows that the Politician's Week is an important arena where patient organisations, together with one or more companies, seek to frame policy debates on certain diseases and treatments, especially cancers. Between 2014 and 2018, 8.7% (n = 116) of all payment reports pertained to the Politician's Week, with a total value of €704,763 (10.9%). Nineteen patient organisations (24.7%) received funding from 22 companies (46.8%). The companies mostly contributed to "events" organised by patient organisations (51.0%; €359,458), followed by "partnership arrangements" between patient organisations and industry (23.2%; €163,433). The goals of the Politician's Week payments were mainly "advocacy and disease awareness" attracting 46.6% (€327,938), followed by "policy engagement" (22.2%; €156,643) and "communication" (20.0%; €140,776). About half of the funding during the Politician's Week concerned neoplasms (51.1%; €360,186), mostly cancer in general (all through The Network Against Cancer) (56.8%; €204,694). Payments combining "policy engagement" and neoplasms attracted 21.3% (€150,455) of all funding during the Politician's Week, representing as much as 73.6% of the total funding for "policy engagement" between 2014--2018.

Notably, 68.1% (n = 79) of all reported Politician's Week payments pertained to activities co-funded by more than one company (52.8%; €372,154), often targeting policy- and decision-makers through "advocacy" (29.2%; €108,563) or "policy engagement" (27.6%; €102,882). Co-funded activities could involve as many as twelve companies, for example, aiming to lift the issue of regional inequalities in the use of cancer drugs onto the political agenda prior to the September 2018 parliamentary elections; or, as in 2015, a seminar on the "patient perspective" which, in addition to cancer patient organisation representatives, included speakers such as the Minister for Health and other high-level politicians, and the Chairpersons of the Swedish Medical Association and the Swedish Association of Health Professionals.

Commercial motives for funding {#sec016}
------------------------------

[Table 6](#pone.0235021.t006){ref-type="table"} shows the concordance between commercialisation of drugs and the funding of patient organisations in the ten most funded disease areas (including cancer in general) for the top ten donors overall. If a company marketed at least one drug in a disease area, there was an 83% chance that it supported a patient organisation in the disease area (κ = 0.78, 95% confidence interval: 0.66--0.90). Companies only supported patient organisations in disease areas linked to their drug portfolio. AbbVie's support of Hemophilia patient advocacy appears at first to be an exception to this rule; however, hundreds of hemophilics in Sweden were infected by hepatitis C in the 1980s due to the use of virus-contaminated blood in transfusions, and AbbVie markets hepatitis C drugs.

10.1371/journal.pone.0235021.t006

###### Drug commercialisation and patient organisation funding in the ten most funded disease areas for the top ten drug industry donors in Sweden (2014--18).

![](pone.0235021.t006){#pone.0235021.t006g}

              Breast can.   HIV     Blood can.   Gener. can.   Diab.   Prost. can.   Hemo-ph.   Rheu-ma.   Enter., Col., Croh.   Psor.                                                                                                             
  ----------- ------------- ------- ------------ ------------- ------- ------------- ---------- ---------- --------------------- ------- ------- ------- ------- ----------------------------------------- ------- ------- ------- ------- ------- -----------------------------------------
  Pfizer      Y             Y       N            N             Y       Y             Y          Y          N                     N       N       N       Y       Y                                         Y       Y       N       Y       Y       Y
  AbbVie      N             N       Y            Y             Y       Y             Y          Y          N                     N       Y       Y       Y       N[^3^](#t006fn003){ref-type="table-fn"}   Y       Y       Y       Y       Y       Y
  Sanofi      N             N       N            N             N       Y             Y          Y          Y                     Y       Y       Y       N       N                                         N       Y       N       N       N       Y
  Roche       Y             Y       N            N             Y       Y             Y          Y          N                     N       N       N       Y       Y                                         Y       Y       N       N       N       N
  Novartis    Y             Y       N            N             Y       Y             Y          Y          N                     Y       N       N       Y       Y                                         Y       Y       N       N       Y       Y
  GSK         N             N       Y            Y             N       N             N          N          N                     N       N       N       N       N                                         N       N       N       N       N       Y[^4^](#t006fn004){ref-type="table-fn"}
  Janssen     N             Y       Y            Y             Y       Y             Y          Y          Y                     Y       Y       Y       N       N                                         Y       Y       Y       Y       Y       Y
  Bayer       N             N       N            N             N       N             Y          Y          Y                     Y       Y       Y       Y       Y                                         N       N       N       N       N       N
  Celgene     N             Y       N            N             Y       Y             Y          Y          N                     N       N       N       N       N                                         Y       Y       N       N       Y       Y
  **Amgen**   **Y**         **Y**   **N**        **N**         **Y**   **Y**         **Y**      **Y**      **N**                 **N**   **Y**   **Y**   **N**   **Y**                                     **Y**   **Y**   **N**   **N**   **N**   **Y**

^1^ Funding: yes/no

^2^ Drug(s): yes/no

^3^ See text for details

^4^ GSK markets topicals to treat skin conditions: Betnovat (approved 1965), Dermovat (1976) and Flutivate (1993)

To further investigate the possible link between commercial motives and funding, we assessed the correlation between the number of new drugs in 2014--2018 marketed by LIF companies in different condition areas and payments to patient organisations in those condition areas. Overall, 139 new drugs were marketed by LIF companies (n = 42). As many as one third (n = 46) were cancer drugs, followed by drugs for treating endocrine, nutritional and metabolic disorders (n = 23; 16.5%), and infectious and parasitic disorders (n = 19; 13.7%). Together, these three condition areas accounted for 56% of the funding over the study period ([Table 5](#pone.0235021.t005){ref-type="table"}). In contrast, there were only three new drugs for treating mental, behavioural and neurodevelopmental disorders, and only one for treating ophthalmologic conditions. Across condition areas, there was a very strong, positive monotonic correlation between the number of new drugs marketed by LIF companies and the number of payments (R~s~ = 0.85, n = 16, p = 0.00003) and the value of those payments (R~s~ = 0.78, n = 16, p = 0.0004). There was also a very strong, positive monotonic correlation between the number of LIF companies marketing new drugs in different condition areas and the number of payments (R~s~ = 0.84, n = 16, p = 0.00005) and the value of those payments (R~s~ = 0.77, n = 16, p = 0.0005) in those condition areas. Results were similar for the subset of LIF companies (n = 30) that marketed new drugs (n = 118; 85%) and reported payments over the study period (€5,868,363; 90.0%): R~s~ = 0.84--0.75, n = 16, p\<0.0009, for all analyses.

Discussion {#sec017}
==========

This study's finding of close relations between patient organisations and pharmaceutical companies is consistent with what has been reported from other countries, including the UK \[[@pone.0235021.ref004], [@pone.0235021.ref026]\], United States \[[@pone.0235021.ref013], [@pone.0235021.ref014], [@pone.0235021.ref017], [@pone.0235021.ref028], [@pone.0235021.ref035]\], Australia \[[@pone.0235021.ref011], [@pone.0235021.ref027]\], Canada \[[@pone.0235021.ref012]\], Italy \[[@pone.0235021.ref036]\] and Finland \[[@pone.0235021.ref029]\]. Between 2014 and 2018, 77 Swedish patient organisations were reported to receive support from 46 companies, involving 1,337 payments with a cumulative value of roughly €6.4m. In addition, there were 75 (5.3%) payments reported which lacked information on the value of the payment, and which were therefore excluded from the analysis. The support was dominated by small payments, many of which were provided to cover costs of events organised by patient organisations, also consistent with findings from other countries \[[@pone.0235021.ref026], [@pone.0235021.ref027]\]. However, our data shows how even small payments may result in substantial financial support from industry since companies may co-fund projects, or one company may repeatedly fund the same or similar projects.

To contextualise our findings, and to enable broader generalisations, we tabulate selected features of industry payments in Sweden (this study) and the UK (reported in previous study using similar methodology) \[[@pone.0235021.ref026]\] ([Table 7](#pone.0235021.t007){ref-type="table"}). Taking population size into account, the total value of payments was about 1.5 times greater in the UK, and the number of payments 1.9 times greater. There are two likely contributors to this difference. First, there were more reporting companies and recipient patient organisations in the UK. This may reflect country differences in, for example, drug commercialisation strategies (e.g., leading global role of UK drug market), government administration (e.g., healthcare in the UK is devolved to England, Scotland, Wales and Northern Ireland, possibly potentiating UK country-specific patient organisations) and availability of other funding (e.g., government funding seems more prominent in Sweden, possibly reducing the need for commercial sources of funding \[[@pone.0235021.ref033]\]). Second, large-size payments were more common in the UK, and they were often of a greater value, as evidenced by the larger median and upper quartile values. Notably, many large-size payments in the UK were linked to research-related activities which accounted for 25% of the value of payments but only 3% of the number of payments. In Sweden, we found almost no funding of research-related activities. In contrast, most funding (61%) went to public involvement activities, encompassing communication, advocacy, campaigning, disease awareness and policy engagement, which typically involves smaller-size payments. This finding suggests marked country-differences in the role of patient organisations in the development of new medicines.

10.1371/journal.pone.0235021.t007

###### Comparison of reported drug company payments to patient organisations in Sweden and the UK.
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  Selected variables                     Sweden (2014--18)        UK (2012--16)
  -------------------------------------- ------------------------ ---------------------
  Population size                        \~ 10m                   \~ 65m
  Value of payments, €                   \~ 6.4m                  \~ 65.1m
  No. of payments                        1337                     4572
  Median (IQR)                           2 411 (1 024 to 4 569)   5 112 (686--11 984)
  No. of companies                       46                       64
  No. of patient organisations           77                       508
  Funding by top 10 companies            68%                      69%
  Public involvement                     61%                      31%
  Support to patients                    6%                       6%
  Research-related                       1%                       25%
  Neoplasms                              38%                      36%
  Endocrine, nutritional and metabolic   9%                       11%
  Infectious and parasitic               9%                       8%

Nevertheless, some striking similarities existed in funding patterns in Sweden and the UK. The hierarchy of funding across condition areas was very similar, with the same top 3 condition areas receiving virtually identical shares of funding in the two countries, including 38% and 36% for neoplasms in Sweden and the UK, respectively. This finding suggests that strong commercial motives pattern companies' funding decisions, including an impetus to support cancer patient advocacy following the many cancer drug launches \[[@pone.0235021.ref035], [@pone.0235021.ref037]\]. However, our study further strengthens this argument. First, we show how companies tend to invest selectively and heavily in diseases linked to their drug portfolios, which shaped the overall pattern of funding across conditions and diseases. Second, we show a very strong correlation between, on the one hand, the number of new drugs and number of companies marketing new drugs in different condition areas and, on the other hand, the payments to patient organisations in different condition areas.

Another striking resemblance between Sweden and the UK was the concentration of funding across donors. In Sweden, only ten companies provided 68% of reported funding; in the UK this was 69%. The picture of a limited number of companies dominating relations is strengthened by findings from the UK showing high concentration of payments at the donor level to healthcare professionals (50% for the top 10 companies) \[[@pone.0235021.ref038]\] and organisations, such as hospitals and primary care centres, (59% for the top 10 companies) \[[@pone.0235021.ref039]\].

The broad picture, then, is of relatively few companies dominating relations by channelling their funding to patient organisations (and most likely other actors) in disease areas linked to their drug portfolios. As a consequence, much funding has been awarded to organisations for (some) cancer patients, such as those suffering from breast, blood or prostate cancers, but also diabetes and HIV. In stark contrast, limited funding goes to organisations for patients facing other major public health challenges, such as mental illness, but for which there have been few or no recent drug launches. Indeed, the top ten areas in terms of disease burden in Sweden in 2017 were ischemic heart disease (8.5% of total Disability-Adjusted Life Years), low back pain (6.1%), stroke (4.2%), headache disorders (3.9%), diabetes (3.7%), Alzheimer's disease (3.6%), COPD (3.6%), falls (3.3%), depressive disorders (3.1%) and lung cancer (2.8%) \[[@pone.0235021.ref040], [@pone.0235021.ref041]\]. Yet, diseases of the circulatory system only amassed 4.6% of the value of payments compared to cancer's 37.5%, despite ischemic heart disease being the leading cause of death and disability in Sweden (although decreasing since 2007), whilst mental, behavioural and neurodevelopmental disorders only received 0.7% of all funding, and depressive disorders were not represented at all.

A concern with this commercially patterned funding is how it may create inequalities between patient organisations representing different diseases not only in terms of differential resources but also differential access to medical and political expertise and the media \[[@pone.0235021.ref011]\]. This risk is exemplified by the extensive joint campaigning and lobbying around certain diseases, especially cancers, during Sweden's annual Politician's Week. At this political, social and media event certain patient organisations, with support from companies, gain access to politicians and other policy- and decision-makers as well as the media. We found that 10.9% of all funding, and 14.9% of all cancer patient group funding, concentrated on the Politician's Week, and a substantial portion of this went to policy engagement. The Politician's Week payments also underscores the importance of taking into account the industry-level agenda for understanding funding patterns. Thus, as many as twelve companies could fund a single event targeting high-level policy and decision-makers.

In addition, we believe that the close link between funding and commercialisation are concerning in light of the uncertainty around the therapeutic value of many new drugs \[[@pone.0235021.ref042], [@pone.0235021.ref043], [@pone.0235021.ref044], [@pone.0235021.ref045], [@pone.0235021.ref046]\]. The problem of therapeutic uncertainty was exemplified by the EMA's recent withdrawal of the soft tissue cancer drug Lartruvo--which the EMA had approved in 2016 on the basis of preliminary data--after the company failed to demonstrate the drug's benefits in a post-authorisation confirmatory trial \[[@pone.0235021.ref047]\]. More generally, a recent study found that more than half of randomised controlled trials for cancer drugs in Europe approved in 2014--2016 had flaws likely to exaggerate treatment benefits \[[@pone.0235021.ref048]\]. Only one-quarter measured survival as a key outcome, and fewer than half reported on patients' quality of life. Ten of these new cancer drugs--Cometriq, Mekinist, Zydelig, Vargatef, Imbruvica, Kyprolis, Darzalex, Ibrance, Opdivo and Empliciti--were marketed by companies that supported a corresponding Swedish patient organisation and/or the Network Against Cancer. The support included several key cases of policy engagement. We cannot make judgements regarding the impact of industry funding on any particular patient organisation or activity. However, there is arguably a danger that patient organisations--who are unlikely to have access to all trial documentation for novel drugs, nor the capacity to undertake independent review of this material--may become direct or indirect champions of drugs that are putting health systems under great financial strain but whose therapeutic benefits remain uncertain.

Prior research has debated the advantages and shortcomings of industry self-regulation and government regulation for ensuring public disclosure of payments to patient organisations. For example, Kang et al \[[@pone.0235021.ref028]\] suggested implementing a legal disclosure requirement in the United States modelled on the Physician Payments Sunshine Act, rather than self-regulation, to ensure centralised payment reporting by companies because government regulation is better at compelling universal compliance. However, the Swedish example shows that a centralised database can in principle be achieved with self-regulation. The Swedish example also shows that national drug industry trade groups can, should they chose to do so, go beyond the rules set out by the industry at the European level that only requires of companies to disclose shorter descriptions of payments to patient organisations on their websites on an annual basis \[[@pone.0235021.ref025]\]. In April 2020, the Swedish pharmaceutical industry trade group updated its Code of Practice with some further innovations that could also be adopted by other countries \[[@pone.0235021.ref049]\]. Most importantly, companies in Sweden should now report payments to individual 'expert' patients and caregivers in the database in addition to the payments to patient organisations. Moreover, companies are no longer allowed to pay for patient organisations' costs for travel, accommodation and food at meetings and conferences, unless the patient organisation representatives are acting as consultants for the company. This latter rule extends the ban that already existed on paying for health professionals' costs for travel, accommodation and food at meetings and conferences \[[@pone.0235021.ref049]\].

It is tempting to speculate that the industry's more stringent rules and disclosure requirements in Sweden compared to, for example, the UK \[[@pone.0235021.ref022], [@pone.0235021.ref026]\] relate to Sweden's historically more transparent approach to government and business regulation, including in the pharmaceutical area \[[@pone.0235021.ref050]\]. However, we note that for the disclosure of payments to healthcare professionals and organisations it is the industry in the UK, but not in Sweden, that established a centralised database of payments, and that several European countries have opted for government regulation to guarantee public disclosure of payments to healthcare professionals \[[@pone.0235021.ref023]\]. This underscores the point that Sweden's self-regulatory system also has significant room for improvement \[[@pone.0235021.ref032]\]. Most pertinent to this study, disclosure databases need to be downloadable in an analysable format (e.g. CSV) to permit efficient and independent analysis. In addition, there is no reason why payment reports should be deleted after three years as is permitted under the current rules. Much can be also done to improve the standardisation and consistency of reporting, for example by linking payment descriptions to pre-established payment categories and goals; ensuring that costs are reported in the same way by all companies; and that information is always complete and represent actual costs (see below); and requiring that companies specify--in a standardised way--the disease or diseases in relation to which the payment is made. Finally, the fact that more than 5% of reports lacked clear information on the value of the payment demonstrates the need for improving compliance and quality control of the database.

Limitations and strengths {#sec018}
-------------------------

One key limitation of our study is that we had to rely on the information provided by companies with no possibility of independently verifying the data. Furthermore, whilst most drug companies active in Sweden are trade group members or subscribe to the Code, and are therefore expected to report in the database, there are exceptions, e.g. Vertex and Gedeon Richter; therefore, our study likely underestimates the volume of payments. A further limitation is that many companies appear to enter information in the database after a formal arrangement between parties has been reached, but before the payment has been made, which means they report expected or maximum costs rather than the actual cost. This is a major limitation because we cannot know if there are differences between expected or maximum costs and the real costs. Another limitation is that each data entry was extracted and coded by one author, but our spot checks by a second author did not identify any discrepancies. Finally, we had to exclude 75 reports (5.3%) that lacked information on the value of the payment. Because of these limitations the values we present should be interpreted with some caution.

A further limitation pertains to our analysis of the association between drug commercialisation and industry funding across conditions and disease areas. Most importantly, we cannot exclude that some of the observed differences are caused by differences in patient organisations' willingness to accept commercial funding. Related to this, we cannot know what effect, if any, funding had on patient organisations. Future studies should therefore increasingly investigate the perspectives and motives of patient organisations and their representatives \[[@pone.0235021.ref011]\].

That said, the industry payment reports in Sweden have clear advantages compared to previously used data sources. Most importantly, Sweden's centralised and searchable database of payments means greater transparency and greater certainty that all disclosures are included in the analysis. Furthermore, our impression is that the Swedish database contains more detailed descriptions of the payments compared to the reports published on company websites. This seems to translate into less ambiguity regarding the purpose of the funding. Indeed, compared to the UK, likely as a result of more detailed information, much fewer payments were coded as unclear with respect to the goal of funding (0.9% vs. 7.6%). The more detailed information also allowed us to characterise the extensive patient organisation-industry joint campaigning during a national lobbying event that merits follow up in future research.

Finally, a key strength of our study is the use of the same methodology as in the previous UK study \[[@pone.0235021.ref026]\] which allowed us to identify similarities and differences in the pattern of funding between the countries. Future research should collect and analyse comparable data from a larger sample of countries to improve the generalisation of results.

Conclusion {#sec019}
==========

This Swedish study reveals close and widespread ties between patient organisations and drug companies. The broad picture is of a relatively limited number of companies dominating relations by supporting patient organisations in disease areas linked to their drug portfolios. The Swedish disclosure initiative's online database has clear advantages for identifying and understanding the nature of industry funding, but the lack of downloadability and standardisation made the analysis burdensome. It is possible that the close ties between patient organisations and companies reflect coinciding interests. However, because funding is commercially motivated it will create inequalities between patient organisations in different disease areas even if there are coinciding interests between donors and recipients. Furthermore, the strong association between drug commercialisation and industry funding is arguably problematic in light of the uncertainty surrounding the therapeutic value of many new and typically expensive drugs.

Supporting information {#sec020}
======================

###### Coding manual for payment categories and goals.

(DOCX)

###### 

Click here for additional data file.

###### Drug industry funders of Swedish patient organisations (2014--18).

(DOCX)

###### 

Click here for additional data file.

###### Top 10 drug industry payments to Swedish patient organisations (2014--18).

(DOCX)

###### 

Click here for additional data file.
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Dear Dr. Mulinari,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In addition to the points raised by the reviewers there some additional comments that I have that the authors should address:

Although the requirements from the EFPIA may be the most comprehensive available that does not necessarily make them optimal and beyond calling for reports to be made available in a downloadable format the authors should suggest other possible changes that should be made to the information that EFPIA requires.Did the two authors extract the data independently and how were disagreements resolved?Page 8, line 17: When the authors say \"target the disease\" does that mean that the particular disease has to be an approved indication for the drug?What statistical software was used and what level of significance was used?Pages 23-24: Some of the material from page 23, line 11 to page 24, line 10 should be divided up between Methods and Results. The purpose of the Discussion is to contextualize the results not to present new results. (The material from page 23, line 15 to page 24, line 1 does belong in the Discussion.)Page 26, line 12: It should be \"media\" not \"medial\".

Please submit your revised manuscript by Jul 06 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Joel Lexchin, MD

Academic Editor
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors provide a descriptive analysis of pharmaceutical company funding of patient groups in Sweden. They took great pains to extract data from an online industry website where payments to patient groups are disclosed. Having participated in creating a similar database in Australia, I can well appreciate the pains the authors took to extract these data and the value in having such a dataset now publicly available and downloadable. I would encourage the authors to create a DOI for their dataset and to find an institutional repository to make this available. Beyond academia, it has great value to journalists and also patient groups.

The authors well-situate the current study internationally and clearly articulate the contribution this analysis will make. This analysis, while it replicates one conducted in the UK and echoes similarly analyses in Australia and the US, provides important comparative data. It also provides fascinating local context with the descriptive analysis of "Politician's Week."

The most important contribution perhaps is the analysis of the relationship between a drug company's product portfolio and patterns in how payments to patient groups are allocated.

Overall, the study is clearly reported and rigorously conducted. I make the following minor comments.

Abstract:

\- Mention country in the abstract text

Introduction:

\- Suggest removing "potential" as adjective for "conflict of interest" (line 7).

\- The first paragraph could perhaps more explicitly describe the concerns related to patient group-industry relationships and the broad implications for society/policy/health. Perhaps the authors could cite a concrete example that illustrates the concern about relationships (e.g. supporting policy positions that favour drug companies).

Methods:

\- What was the justification for the 5-year period? Is this the time frame for which data are available? In either case, it would be interesting to know when LIF began reporting and the impetus to begin reporting (though better to describe in the Introduction, perhaps).

\- In the section, "Association between drug commercialisation and industry funding," I did not understand the distinction (or the relationship?) between the analysis described in the first paragraph compared with the second. The second analysis described seems more robust, comprehensive and also clearer in terms of how the relationship between commercialization and funding of patient groups was assessed.

\- I would appreciate more information as to how the categories for "Category" and "Goal" were developed. I realize that the authors relied on a scheme developed in a past analysis, but at minimum, it would be valuable to describe whether the authors relied on categories/goals developed by the industry reporters, or whether it was more of an inductive categorization the authors conducted. A supplementary file with the coding manual defining each of these categories would also be helpful.

Results

\- I am curious about your choice of the word "collaboration" to describe the patient advocacy-industry relationships, for example, at the beginning of the "46 pharmaceutical companies reported 1,412 collaborations with the local, regional or national branches of 77 patient organisations." Is this the authors' word choice or the way it is described in the database?

\- Sentence on page 10, lines 12-15 I think should be two sentences (period instead of comma after Table 2).

\- For the sentence, "Pfizer was the major donor with 14.8% of the reported funding whereas AbbVie had the greatest number of payments (10.9%; n=146)," perhaps provide numerators/denominators to distinguish between the two measures

\- In Table 3, could you clarify whether the % of funding measure for the columns "Value" and "Main donor" are percent of the donor's total funding of patient groups or percent of total pharma funding received? For all Tables (3, 4 and 5), it would be helpful to have a row at the top with the "Totals" to provide context for the proportions (which I assume are column proportions?)

\- Table 4 is informative and I particularly appreciate the illustrative examples. However, I found the information much more meaningful for the "Goal" categories. I would suggest removing the "Category" data from the table and consolidating most of the categories and either presenting them in a separate table or reporting in the narrative text. Specifically, I wonder whether there is a meaningful difference between "Sponsorships" and "Contributions to costs of event" (a form of sponsorship), "Support and help" (arguably the point of sponsorship) and "Grants." All seem to be a lump sum provided by the company for the patient groups' activities. Could these be grouped? I don't really understand how "Partnership Arrangements" is defined. The remaining categories are self-evident and clearly distinct.

\- The phrase, "ten most funding drug companies" (used throughout) might be more clearly rephrased as "top ten contributors" or something

Discussion

\- The Discussion is thoughtful and comprehensive.

\- For Table 7 (which is helpful), could you provide additional rows to show the value and number of payments per capita? (e.g. value/population size)

\- I would add to the discussion of accessibility of public disclosure data that it should not only be downloadable, but in an analyzable format. For example, for a long time in Australia, PDFs could be downloaded, but make analysis impossible. All data should be provided in CSV format for download.

Reviewer \#2: Summary

The researchers seek to add to a body of country-specific research on pharmaceutical industry funding of patient advocacy organizations by describing how this funding is distributed among patient organizations in Sweden and assessing whether the financial support that companies provide has a commercial agenda that could influence patient advocacy. A secondary purpose is to evaluate the industry's centralized database of pharmaceutical industry donations, which is unique to Sweden. The results support the authors' claim that investments in the patient community are significant and the patterns of funding indicate commercial agendas. While a demonstrated effect on advocacy is neither possible from the data nor claimed, the data analysis and discussion clearly illustrate a mismatch between funding patterns and the main objectives of national health policies: therapeutic need, therapeutic value and fair resource distribution.

The methodology is appropriate and follows that of a similar study in the UK that three of the four authors co-authored. This allowed for comparable units of analysis between the two and direct comparison of the two data sets in the discussion. This is a positive feature and begins an important investigation of industry strategies of product promotion that crosses borders.

The research is carefully conducted, the text is clearly written, and the data support the authors' claims. I recommend publication with minor clarifications, corrections, and additions.

Issues to be addressed

Major

• Tables 1 through 5 provide summary data; the raw data is not provided (i.e., listing by year of individual donations from each company to each organization with the inflation and currency exchange rate noted for each year).

• Text-table discrepancy: In Table 5, second row on p 15, the number of supporting companies is 17; in the text, p 19, line 7 says "cancers in general" had 16 funders.

• Page 30, line 1: Reference 1., Democratizing Health, lists two co-editors; Hans Löfgren is also an editor (the first of three listed on the book cover).

Minor

\- Pp 2-3, line 2:25, 3:1-2: This list of conditions is confusing. Use colons instead of commas to distinguish the three top conditions from the sub-conditions within them.

\- Change "North America" to "United States" on page 5, line 1, referring to the spur in research on disclosure policies in different countries (Canada and Mexico do not have the same level of disclosure as the U.S. and reference \#27, p 32, l 20-22 is to a U.S. study).

\- In Table 3, the "1.6 Million Club" for women over the age of 46 attracted substantial funding from 8 companies, but the relevant condition(s) is/are not obvious. Do the supporting companies and/or the events supported suggest what motivated these donations? How were donations to this group, and any others with ambiguous health constituency handled in the coding?

\- In tables 2, 3, 4, 5 and S1, clearly indicate the meaning of column heading "n(%)". I believe "n" refers to "Number of Reports" but had to comb the text to determine this.

\- Check the manuscript for words that run together, e.g., cover page abstract: "betweennew drugs", "Theassociation between" and "commercialisationand industry"

Questions and comments for the authors

1\) The top payment category is "contributions to cost of events organized by recipients or third parties." Do the authors know who these third parties are? Pharmaceutical companies often work in concert with public relations firms in their collaborations with groups (see ref 15, 187-188). Essentially the "third party" PR firm works for the company and shapes the event to further the marketing goals of the company; simply referring to a "third party" suggests a third independent actor.

2\) A paragraph discussing the role of industry Codes of Practice and the relationship between voluntary and legally mandated disclosures would be helpful. In particular, the reader may question why the database in Sweden is centralized when other countries under EPFIA use decentralized databases. What are the avenues for achieving centralized (and downloadable) databases? How important are legal interventions to opening up transparency? Also, although the EPFIA and Swedish codes cited in the article are appropriate to the time period studied, both codes have been updated (EPFIA revised 2019; IFPMA update to take effect May 2020). A note on any changes to the codes would underline the fact that these codes are continually reviewed and would be valuable to researchers undertaking future investigations, especially if changes affect transparency in patient group relations. Finally, the Ethical Rules for the Pharmaceutical Industry in Sweden (2015: 57) states that, "Short versions of all contracts and agreements should also be available in the LIF Cooperation Database when activity is ongoing and at least for one month after the project is concluded." Were any of these contracts viewed? If so, are they useful for assessing the industry's use of the activities for commercial advantage?

3\) The UK-Sweden comparison and the finding that substantial funding is devoted to one advocacy event could be listed in the "strengths" section. Research conducted in a country where English is not the dominant language or culture is an especially useful addition to the existing body of funding disclosure analyses.

4\) Similarly, the focus on funding the national lobbying event, "Politicians' Week" Is a novel finding and a strength that merits follow up in future research (e.g., federal governments in Canada and the US both have "Lobby Days" or "Advocacy Days", which attract patient advocacy groups with industry funding).

Re: 2. Rigour of statistical analysis: In my assessment the use Cohen's k and Spearman's rank order correlation \[page 9\] are appropriate and support the authors\' conclusions; however, I am a qualitative researcher and have limited familiarity with the choice and use of statistical tests for measuring associations.

Reviewer \#3: This paper makes an important contribution to understand the recent history of patient organisation funding by the pharmaceutical industry in Sweden. It uses the appropriate level of nuance and analytical tools to describe the results and assess the association between companies\' commercial interests and patient group funding, with a particular focus on recently marketed medicines. Moreover, it also confirms a number of previously observed trends with regards to industry funding of patient organisations in the UK.

One minor suggestion is to clarify on page 4, line 18 that EFPIA represents research-based pharmaceutical companies. The same with LIF (page 5, line 20). Could the authors clarify whether this study is likely to capture most of the companies supporting patient groups in Sweden, or whether there are important sub-populations of companies (i.e. generics?) that are not described here. Generic companies may, but are unlikely to, also support patient organisations. For example, generic industry associations support other groups such as universities through funded research chairs. Thank you.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Quinn Grundy, Assistant Professor, University of Toronto

Reviewer \#2: Yes: Sharon Batt, PhD

Reviewer \#3: Yes: Katrina Perehudoff

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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4 Jun 2020

Comments from Editor

In addition to the points raised by the reviewers there some additional comments that I have that the authors should address:

1 Although the requirements from the EFPIA may be the most comprehensive available that does not necessarily make them optimal and beyond calling for reports to be made available in a downloadable format the authors should suggest other possible changes that should be made to the information that EFPIA requires.

Response: Thank you. We very much agree with this comment, and we have added two new paragraphs in the Discussion to address it. Please refer to our response to Reviewer 2.

2 Did the two authors extract the data independently and how were disagreements resolved?

Response: We did not extract the data independently but divided the data extraction between us. However, when AV (second author) collected the data from 2017-2018 in April and May 2019 he checked the data collected by SM (first author) from June 2016 to December 2016 and found no discrepancies. We have added this to the Methods. We have also added that the lack of confirmation for all data is a Limitation (in the Limitation section).

3 Page 8, line 17: When the authors say \"target the disease\" does that mean that the particular disease has to be an approved indication for the drug?

Response: Thank you for this question. Yes, our definition was based on the approved indication (i.e. it did not include off-label uses) but, at the same time, it was technically broader than the approved indication which can be quite narrow. For example, idelalisib (Zydelig) is approved in a subset of patients with CLL or follicular lymphoma, but we coded it as a blood cancer drug. To clarify that we based our judgment on the approved indication, we have reworded as follows (changes in bold):

"We used information on approved indications to determine whether or not companies marketed at least one drug in each of the ten selected diseases. For a drug to be considered marketed in a disease it had be indicated for the disease, e.g. drugs approved in HIV/AIDS patients for combating non-HIV infections, such as fungal infections, were not HIV drug. Similarly, analgesics indicated for cancer patients were not cancer drugs."

4 What statistical software was used and what level of significance was used?

Response: We have added 'A p-value below 0.05 was considered significant. Prism 8.2.1 for Macintosh (GraphPad Software Inc.) was used all statistical analyses.'

5 Pages 23-24: Some of the material from page 23, line 11 to page 24, line 10 should be divided up between Methods and Results. The purpose of the Discussion is to contextualize the results not to present new results. (The material from page 23, line 15 to page 24, line 1 does belong in the Discussion.)

Response: We understand the point raised. However, we feel we are not presenting any new data here; we are simply summarising some key points. Importantly, all the data in Table 7 can be found in Tables 1-5 and in our UK study. For this reason, we would prefer keeping the Discussion as is, unless the Editor advises strongly against it.

6 Page 26, line 12: It should be \"media\" not \"medial\".

Response: Thank you

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response: The complete dataset will be available here: <https://zenodo.org/record/3875140#.Xtit3S2HJm9>

DOI: 10.5281/zenodo.3875140

Reviewers\' comments:

Reviewer \#1: The authors provide a descriptive analysis of pharmaceutical company funding of patient groups in Sweden. They took great pains to extract data from an online industry website where payments to patient groups are disclosed. Having participated in creating a similar database in Australia, I can well appreciate the pains the authors took to extract these data and the value in having such a dataset now publicly available and downloadable. I would encourage the authors to create a DOI for their dataset and to find an institutional repository to make this available. Beyond academia, it has great value to journalists and also patient groups.

The authors well-situate the current study internationally and clearly articulate the contribution this analysis will make. This analysis, while it replicates one conducted in the UK and echoes similarly analyses in Australia and the US, provides important comparative data. It also provides fascinating local context with the descriptive analysis of "Politician's Week."

The most important contribution perhaps is the analysis of the relationship between a drug company's product portfolio and patterns in how payments to patient groups are allocated.

Overall, the study is clearly reported and rigorously conducted. I make the following minor comments.

Response: Thank you very much for the positive assessment of our study. The complete dataset will be available here: <https://zenodo.org/record/3875140#.Xtit3S2HJm9>

DOI: 10.5281/zenodo.3875140

Abstract:

\- Mention country in the abstract text

Response: This has been added.

Introduction:

\- Suggest removing "potential" as adjective for "conflict of interest" (line 7).

Response: We have removed 'potential'

\- The first paragraph could perhaps more explicitly describe the concerns related to patient group-industry relationships and the broad implications for society/policy/health. Perhaps the authors could cite a concrete example that illustrates the concern about relationships (e.g. supporting policy positions that favour drug companies).

Response: Thank you for this suggestion. We have added an example of this:

"For example, several industry-funded patient groups at the European Union level supported the industry's efforts to relax the ban on direct-to-consumer advertising, but this agenda was strongly opposed by patient groups that did not accept industry funding \[21\]."

Methods:

\- What was the justification for the 5-year period? Is this the time frame for which data are available? In either case, it would be interesting to know when LIF began reporting and the impetus to begin reporting (though better to describe in the Introduction, perhaps).

Response: The 5-year period was selected for two main reasons. One reason was data availability. As we note, industry rules allow reports to be deleted after three years, which sets a limit on the time frame for which data was available. Second, we felt that 3 years would not be enough to capture the association between commercialisation and funding, but we expected that 5 years could be reasonable and manageable. Therefore, we collected data at two points in time to ensure we had 5 years of data. We have added a sentence explaining this:

"We selected a 5-year period in order to have a fairly large but still manageable sample, but also because industry rules allow reports to be deleted after three years which limits data availability"

LIF has had the database in place since 2005. We have added this information to the introduction.

Regarding the impetus to begin reporting, we believe that a statement about this would require a separate study. LIF says that the impetus was its longstanding commitment to transparency, clarity and accountability, but it's possible that the main impetus was protecting the industry and self-regulation from reputational threats. Indeed, when LIF launched the database in 2005, they referred to the recently published report by UK House of Commons Health Committee on the Influence of the Pharmaceutical Industry, and acknowledged that some of the issues raised in the report were relevant to Sweden too.

\- In the section, "Association between drug commercialisation and industry funding," I did not understand the distinction (or the relationship?) between the analysis described in the first paragraph compared with the second. The second analysis described seems more robust, comprehensive and also clearer in terms of how the relationship between commercialization and funding of patient groups was assessed.

Response: Thank you for this comment. We believe the analyses provide different pieces of information that together support the claim of a strong link between drug commercialisation and payments to patient organisations.

The first analysis is about the association between commercialisation of drugs by specific companies, for example Pfizer, and the funding of patient organisations in specific diseases, for example breast cancer. This analysis is important because it shows that companies are funding patient organisations in disease areas linked to their specific drug portfolio. Indeed, the results show that we can quite accurately predict if a drug company will support a patient organisation or not by looking at its drug portfolio in the ten selected diseases, so this provides a quite strong argument for the 'commercialisation thesis'.

The second analysis is about the association between commercialisation of new drugs and payments to patient organisations in broader condition areas. It is important because it shows the overall relationship between the number of new drugs/companies marketing drugs and payments.

In the Discussion we make the following two statements:

1\. 'companies tend to invest selectively and heavily in diseases linked to their drug portfolios, which shaped the overall pattern of funding across conditions and diseases.' (Analysis 1)

2 there is a 'very strong correlation between, on the one hand, the number of new drugs and number of companies marketing new drugs in different condition areas and, on the other hand, the payments to patient organisations in different condition areas'. (Analysis 2)

\- I would appreciate more information as to how the categories for "Category" and "Goal" were developed. I realize that the authors relied on a scheme developed in a past analysis, but at minimum, it would be valuable to describe whether the authors relied on categories/goals developed by the industry reporters, or whether it was more of an inductive categorization the authors conducted. A supplementary file with the coding manual defining each of these categories would also be helpful.

Response: This is an important comment. We have added the following explanation in the Methods:

"In short, the payment category codes were initially devised based on the codes used by EFPIA to categorise pharmaceutical company payments to healthcare organisations (e.g. hospitals, universities, medical associations), specifically, "grants", "contributions to costs of events", "travel, accommodation and registration fees", "fees for service and consultancy", and "sponsorship"'. These codes were then supplemented with an inductive approach for any emerging payment categories that were unique to the patient organisation payment descriptions, such as "support and help" \[26\]. Separately, payment goal was coded based on close iterative reading of payment descriptions and aggregating similar descriptions under the same codes \[26\]. When coding payment goals we looked for the main purpose of activities funded by drug companies."

In addition, we have added a coding manual (S1 Table) defining each of the categories and goals, as suggested by the reviewer. This manual was developed in our previous UK study.

Results

\- I am curious about your choice of the word "collaboration" to describe the patient advocacy-industry relationships, for example, at the beginning of the "46 pharmaceutical companies reported 1,412 collaborations with the local, regional or national branches of 77 patient organisations." Is this the authors' word choice or the way it is described in the database?

Response: The official name of the database is the Collaboration Database. This is indicated in the Abstract and Methods where we use "collaboration database" with quotation marks. However, in light of the reviewer's thoughtful comment, we have replaced 'collaborations' with 'relationships' in the quoted paragraph.

\- Sentence on page 10, lines 12-15 I think should be two sentences (period instead of comma after Table 2).

Response: Thank you.

\- For the sentence, "Pfizer was the major donor with 14.8% of the reported funding whereas AbbVie had the greatest number of payments (10.9%; n=146)," perhaps provide numerators/denominators to distinguish between the two measures

Response: Thank you. We have added the numerator: "Pfizer was the major donor with 14.8% (€954,234) ..." The denominators are in the previous paragraph and in Table 1.

\- In Table 3, could you clarify whether the % of funding measure for the columns "Value" and "Main donor" are percent of the donor's total funding of patient groups or percent of total pharma funding received?

Response: It's the % of total industry funding. We have clarified this in the table by adding footnotes.

For all Tables (3, 4 and 5), it would be helpful to have a row at the top with the "Totals" to provide context for the proportions (which I assume are column proportions?)

Response: We have clarified this in the tables by adding footnotes.

\- Table 4 is informative and I particularly appreciate the illustrative examples. However, I found the information much more meaningful for the "Goal" categories. I would suggest removing the "Category" data from the table and consolidating most of the categories and either presenting them in a separate table or reporting in the narrative text. Specifically, I wonder whether there is a meaningful difference between "Sponsorships" and "Contributions to costs of event" (a form of sponsorship), "Support and help" (arguably the point of sponsorship) and "Grants." All seem to be a lump sum provided by the company for the patient groups' activities. Could these be grouped? I don't really understand how "Partnership Arrangements" is defined. The remaining categories are self-evident and clearly distinct.

Response: We understand the reviewer's concern. However, we have now clearly defined each 'Category' code in S1 Table and also give more detail in Methods (see previous response).

\- The phrase, "ten most funding drug companies" (used throughout) might be more clearly rephrased as "top ten contributors" or something

Response: Thank you very much for this suggestion. We have changed the text accordingly.

Discussion

\- The Discussion is thoughtful and comprehensive.

Response: Thank you very much.

\- For Table 7 (which is helpful), could you provide additional rows to show the value and number of payments per capita? (e.g. value/population size)

Response: The table contains the population size of each country. For Sweden it's about 10m, which makes it very easy to calculate all values/population. For the UK, it's 65m, which is also makes it easy to calculate, especially since the value of payments in the UK is about €65m.

\- I would add to the discussion of accessibility of public disclosure data that it should not only be downloadable, but in an analyzable format. For example, for a long time in Australia, PDFs could be downloaded, but make analysis impossible. All data should be provided in CSV format for download.

Response: Thank you for this very valuable comment. We have added that 'databases should be downloadable in an analysable format (e.g. CSV) to permit efficient and independent analysis.'

Reviewer \#2: Summary

The researchers seek to add to a body of country-specific research on pharmaceutical industry funding of patient advocacy organizations by describing how this funding is distributed among patient organizations in Sweden and assessing whether the financial support that companies provide has a commercial agenda that could influence patient advocacy. A secondary purpose is to evaluate the industry's centralized database of pharmaceutical industry donations, which is unique to Sweden. The results support the authors' claim that investments in the patient community are significant and the patterns of funding indicate commercial agendas. While a demonstrated effect on advocacy is neither possible from the data nor claimed, the data analysis and discussion clearly illustrate a mismatch between funding patterns and the main objectives of national health policies: therapeutic need, therapeutic value and fair resource distribution.

The methodology is appropriate and follows that of a similar study in the UK that three of the four authors co-authored. This allowed for comparable units of analysis between the two and direct comparison of the two data sets in the discussion. This is a positive feature and begins an important investigation of industry strategies of product promotion that crosses borders.

The research is carefully conducted, the text is clearly written, and the data support the authors' claims. I recommend publication with minor clarifications, corrections, and additions.

Response: Thank you very much for the positive assessment of our study.

Issues to be addressed

Major

• Tables 1 through 5 provide summary data; the raw data is not provided (i.e., listing by year of individual donations from each company to each organization with the inflation and currency exchange rate noted for each year)

Response: Thank you. The complete dataset will be available here: <https://zenodo.org/record/3875140#.Xtit3S2HJm9>

DOI: 10.5281/zenodo.3875140

• Text-table discrepancy: In Table 5, second row on p 15, the number of supporting companies is 17; in the text, p 19, line 7 says "cancers in general" had 16 funders.

Response: Thank you so much for spotting this mistake. The correct number is 16.

• Page 30, line 1: Reference 1., Democratizing Health, lists two co-editors; Hans Löfgren is also an editor (the first of three listed on the book cover).

Response: Thank you so much for spotting this mistake.

Minor

\- Pp 2-3, line 2:25, 3:1-2: This list of conditions is confusing. Use colons instead of commas to distinguish the three top conditions from the sub-conditions within them.

Response: Thank you for this suggestion.

\- Change "North America" to "United States" on page 5, line 1, referring to the spur in research on disclosure policies in different countries (Canada and Mexico do not have the same level of disclosure as the U.S. and reference \#27, p 32, l 20-22 is to a U.S. study).

Response: Thank you for this suggestion.

\- In Table 3, the "1.6 Million Club" for women over the age of 46 attracted substantial funding from 8 companies, but the relevant condition(s) is/are not obvious. Do the supporting companies and/or the events supported suggest what motivated these donations? How were donations to this group, and any others with ambiguous health constituency handled in the coding?

Response: Thank you for this question. In many cases we could identify the disease based on the project and payment descriptions. In the case of the 1.6 Million Club, 5 of 32 payments went to osteoporosis disease awareness, 2 payments were linked to cardiovascular disease and 2 to stroke. However, half of the payments to the 1.6 Million Club, worth €108,758, could not be differentiated at the level of a disease, and they were coded as 'Women's health' which is part of the 'Various' condition category. Importantly, these are all reported in Table 5 under 'Women's health'.

\- In tables 2, 3, 4, 5 and S1, clearly indicate the meaning of column heading "n(%)". I believe "n" refers to "Number of Reports" but had to comb the text to determine this.

Response: Thank you. We have clarified this in the tables by adding footnotes.

\- Check the manuscript for words that run together, e.g., cover page abstract: "betweennew drugs", "Theassociation between" and "commercialisationand industry"

Response: Thank you. We have fixed this in the cover page abstract.

Questions and comments for the authors

1\) The top payment category is "contributions to cost of events organized by recipients or third parties." Do the authors know who these third parties are? Pharmaceutical companies often work in concert with public relations firms in their collaborations with groups (see ref 15, 187-188). Essentially the "third party" PR firm works for the company and shapes the event to further the marketing goals of the company; simply referring to a "third party" suggests a third independent actor.

Response: In the Swedish dataset we only found one clear example of using a PR firm. Roche paid a PR firm approx. EUR 500 to organise a prize ceremony event for the colorectal cancer prize which is handed out by the patient organisation every year. In addition, there were a few instances of paying for co-arrangements with the leading medical news outlet in Sweden, 'Dagens Medicin' \[Medicine Today\], including at the Politician's week.

2\) A paragraph discussing the role of industry Codes of Practice and the relationship between voluntary and legally mandated disclosures would be helpful. In particular, the reader may question why the database in Sweden is centralized when other countries under EPFIA use decentralized databases. What are the avenues for achieving centralized (and downloadable) databases? How important are legal interventions to opening up transparency? Also, although the EPFIA and Swedish codes cited in the article are appropriate to the time period studied, both codes have been updated (EPFIA revised 2019; IFPMA update to take effect May 2020). A note on any changes to the codes would underline the fact that these codes are continually reviewed and would be valuable to researchers undertaking future investigations, especially if changes affect transparency in patient group relations. Finally, the Ethical Rules for the Pharmaceutical Industry in Sweden (2015: 57) states that, "Short versions of all contracts and agreements should also be available in the LIF Cooperation Database when activity is ongoing and at least for one month after the project is concluded." Were any of these contracts viewed? If so, are they useful for assessing the industry's use of the activities for commercial advantage?

Response: Thank you for these important comments.

Regarding the last point, we did look at some contracts, but we didn't find them especially informative in terms of understanding the activity better. They were simply more "formal" versions of what was already in the summary database.

We have added the following paragraph to address the reviewer's other comments:

'Prior research has debated the advantages and shortcomings of industry self-regulation and government regulation for ensuring public disclosure of payments to patient organisations. For example, Kang et al \[28\] suggested implementing a legal disclosure requirement in the United States modelled on the Physician Payments Sunshine Act, rather than self-regulation, to ensure centralised payment reporting by companies because government regulation is better at compelling universal compliance. However, the Swedish example shows that a centralised database can in principle be achieved with self-regulation. The Swedish example also shows that national drug industry trade groups can, should they chose to do so, go beyond the rules set out by the industry at the European level that requires of companies to disclose shorter descriptions of payments to patient organisations on their websites on an annual basis \[25\]. In April 2020, the Swedish pharmaceutical industry trade group updated its Code of Practice with some further innovations that could also be adopted by other countries \[49\]. Most importantly, companies in Sweden should now report payments to individual 'expert' patients and caregivers in the database in addition to the payments to patient organisations. Moreover, companies are no longer allowed to pay for patient organisations' costs for travel, accommodation and food at meetings and conferences, unless the patient organisation representatives are acting as consultants for the company. This latter rule extends the ban that already existed on paying for health professionals' costs for travel, accommodation and food at meetings and conferences \[49\].

It is tempting to speculate that the industry's more stringent rules and disclosure requirements in Sweden compared to, for example, the UK \[22, 26\] relate to Sweden's historically more transparent approach to government and business regulation, including in the pharmaceutical area \[50\]. However, we note that for the disclosure of payments to healthcare professionals and organisations it is the industry in the UK, but not in Sweden, that established a centralised database of payments, and that several European countries have opted for government regulation to guarantee public disclosure of payments to healthcare professionals \[23\]. This underscores the point that Sweden's self-regulatory system also has significant room for improvement \[32\]. Most pertinent to this study, disclosure databases need to be downloadable in an analysable format (e.g. CSV) to permit efficient and independent analysis. In addition, there is no reason why payment reports should be deleted after three years as is permitted under the current rules. Much can be also done to improve the standardisation and consistency of reporting, for example by linking payment descriptions to pre-established payment categories and goals; ensuring that costs are reported in the same way by all companies; and that information is always complete and represent actual costs (see below); and requiring that companies specify -- in a standardised way -- the disease or diseases in relation to which the payment is made. Finally, the fact that more than 5% of reports lacked clear information on the value of the payment demonstrates the need for improving compliance and quality control of the database.'

3\) The UK-Sweden comparison and the finding that substantial funding is devoted to one advocacy event could be listed in the "strengths" section. Research conducted in a country where English is not the dominant language or culture is an especially useful addition to the existing body of funding disclosure analyses.

Response: Thank you for this important suggestion. We have added the following paragraph in the 'Limitation and strengths' section:

'Finally, a key strength of our study is the use of the same methodology as in the previous UK study \[26\] which allowed us to identify similarities and differences in pattern of funding between the countries. Future research should collect and analyse comparable data from a larger sample of countries to improve the generalisation of results.'

4\) Similarly, the focus on funding the national lobbying event, "Politicians' Week" Is a novel finding and a strength that merits follow up in future research (e.g., federal governments in Canada and the US both have "Lobby Days" or "Advocacy Days", which attract patient advocacy groups with industry funding).

Response: Thank you for this important suggestion. We have added the following paragraph in the 'Limitation and strengths' section: 'The more detailed information also allowed us to characterise the extensive patient organisation-industry joint campaigning during a national lobbying event that merits follow up in future research'.

Re: 2. Rigour of statistical analysis: In my assessment the use Cohen's k and Spearman's rank order correlation \[page 9\] are appropriate and support the authors\' conclusions; however, I am a qualitative researcher and have limited familiarity with the choice and use of statistical tests for measuring associations.

Reviewer \#3: This paper makes an important contribution to understand the recent history of patient organisation funding by the pharmaceutical industry in Sweden. It uses the appropriate level of nuance and analytical tools to describe the results and assess the association between companies\' commercial interests and patient group funding, with a particular focus on recently marketed medicines. Moreover, it also confirms a number of previously observed trends with regards to industry funding of patient organisations in the UK.

Response: Thank you very much for the positive assessment of our study.

One minor suggestion is to clarify on page 4, line 18 that EFPIA represents research-based pharmaceutical companies. The same with LIF (page 5, line 20). Could the authors clarify whether this study is likely to capture most of the companies supporting patient groups in Sweden, or whether there are important sub-populations of companies (i.e. generics?) that are not described here. Generic companies may, but are unlikely to, also support patient organisations. For example, generic industry associations support other groups such as universities through funded research chairs. Thank you.

Response: Thank you for this important comment.

The LIFs rules have been ratified by the trade group for smaller life companies and the trade group for generic pharmaceuticals and biosimilars manufacturers. However, we found no reported payments from non-LIF companies including generics companies.

In the Limitations section we make the following statement that addresses the important issue raised by the reviewer: 'Furthermore, whilst most drug companies active in Sweden are trade group members or subscribe to the Code, and are therefore expected to report in the database, there are exceptions, e.g. Vertex and Gedeon Richter; therefore, our study likely underestimates the volume of payments.'
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